CD4 and cancer: Therapies that can trigger immune reconstitution via an increased CD4+ T-cell count may potentially decrease morbidity and mortality by lowering the rate of opportunistic infections and AIDS-related malignancies in patients receiving anti-HIV therapy who fail to achieve an increase in CD4+ T-cell count above 200 cells/μL.